YK-11 Research: Androgen Receptors, Follistatin, Myogenic Differentiation and Bone Cell Biology
YK-11 is an experimental steroidal selective androgen receptor modulator investigated in cellular research involving androgen receptor signalling, muscle cell differentiation, follistatin expression and bone forming cells.
It is frequently promoted online as a powerful muscle building compound or myostatin inhibitor. These descriptions extend substantially beyond the available evidence. The best known YK-11 research was conducted in cultured mouse muscle cells. Researchers reported that YK-11 promoted myogenic differentiation and increased follistatin expression through an androgen receptor dependent pathway. A separate laboratory study examined YK-11 in a mouse osteoblast cell line and reported changes associated with cellular proliferation and differentiation.
These findings are scientifically interesting, but neither study demonstrates muscle growth, bone improvement, safety or predictable biological effects in humans. There is no established body of controlled human clinical research defining YK-11 pharmacokinetics, effectiveness, adverse effects or long term risk.
YK-11 should therefore be presented as a highly experimental androgen receptor compound supported mainly by cellular evidence, not as a proven myostatin inhibitor or approved muscle building treatment.
What Is YK-11?
YK-11 is a synthetic steroidal molecule commonly classified as a selective androgen receptor modulator. This structural description distinguishes it from nonsteroidal SARMs such as LGD-4033, RAD-140 and Ostarine MK-2866. Although these compounds are grouped together because they interact with the androgen receptor, they do not share the same chemical framework.
YK-11 contains a steroid derived core structure. Its molecular formula is reported as C25H34O6, with a calculated molecular mass of approximately 430.54 grams per mole. It has also been marketed under the name Myostine. That commercial name should not be confused with myostatin, which is a naturally occurring signalling protein involved in regulating skeletal muscle growth.
A similar name does not demonstrate direct inhibition of myostatin. YK-11 is a synthetic androgen receptor ligand, follistatin is a regulatory protein and myostatin is a growth factor associated with muscle regulation. These are separate biological and chemical entities.
Is YK-11 a Steroid or a SARM?
YK-11 has a steroid derived molecular framework and is commonly described as a steroidal SARM. The terms steroid and SARM refer to different characteristics. Steroid describes the underlying structural framework, while SARM describes an intended or observed pattern of selective androgen receptor modulation.
A compound can therefore possess a steroidal structure while being investigated as a selective androgen receptor modulator. This differs from LGD-4033, RAD-140 and Ostarine, which are nonsteroidal androgen receptor ligands.
The steroidal structure of YK-11 does not prove that its metabolism, tissue distribution or biological effects match testosterone or conventional anabolic steroids. Those questions require direct experimental measurements. It is equally incorrect to assume that classification as a SARM guarantees tissue selectivity. Selectivity must be demonstrated across relevant tissues and experimental systems before it can be interpreted confidently.
YK-11 and Androgen Receptor Signalling
The androgen receptor is a nuclear receptor naturally activated by hormones including testosterone and dihydrotestosterone. When a suitable ligand binds to it, the receptor changes shape, interacts with regulatory proteins and influences gene transcription. The resulting activity depends on the ligand, cell type, receptor concentration, transcriptional cofactors and experimental conditions.
Early cellular research characterised YK-11 as a partial androgen receptor agonist. A partial agonist can activate a receptor but may produce a different maximum response or transcriptional pattern from a full agonist under the same experimental conditions.
YK-11 was reported to activate androgen receptor mediated transcription without producing the conventional interaction between the receptor’s amino terminal and ligand binding regions. This is commonly called the androgen receptor N and C terminal interaction and contributes to transcriptional activity produced by conventional androgen receptor agonists.
The unusual response led researchers to propose that YK-11 may produce a distinct gene selective signalling pattern. Gene selective does not mean muscle exclusive, clinically safe or free from androgenic activity. It describes a laboratory observation involving receptor structure and transcription.
The Principal YK-11 Muscle Cell Study
The most frequently cited YK-11 study was published in Biological and Pharmaceutical Bulletin in 2013. Researchers investigated the compound using C2C12 mouse myoblast cells, an established laboratory model for studying early stages of skeletal muscle differentiation.
Myoblasts are precursor cells capable of differentiating and fusing into multinucleated myotubes under suitable culture conditions. Researchers use C2C12 cells because they provide a consistent system for examining changes in myogenic regulatory proteins, structural muscle markers and cellular differentiation.
The investigators compared YK-11 with dihydrotestosterone and examined several markers connected with myogenic differentiation. YK-11 was reported to promote differentiation in the cultured cells. The study also identified increased follistatin expression and examined whether androgen receptor activity contributed to that response.
This experiment provides evidence that YK-11 can influence androgen receptor associated signalling and differentiation markers within this particular mouse cell model. It does not establish that YK-11 increases human muscle mass or strength.
An intact organism introduces absorption, metabolism, circulation, endocrine feedback, tissue distribution, immune activity and elimination. A response observed in isolated mouse cells cannot define what happens after exposure in a human biological system.
YK-11 and Follistatin Expression
The 2013 study reported that YK-11 increased follistatin expression in C2C12 cells. Follistatin is a regulatory protein capable of binding activin family ligands. It is studied in connection with cellular differentiation, reproductive biology, tissue development and muscle related pathways.
Follistatin can interact with myostatin, although its biology extends well beyond a single myostatin pathway. Researchers explored its role in the YK-11 response by reducing follistatin expression. Interfering with follistatin reduced the reported myogenic response, supporting the conclusion that it contributed to the observed cellular differentiation.
The study also examined androgen receptor involvement. Reducing or blocking receptor activity affected the YK-11 response, indicating that the process depended substantially on androgen receptor signalling.
This is more precise than claiming that YK-11 simply blocks myostatin. The experiment demonstrated increased follistatin expression in cultured mouse muscle cells and found that follistatin contributed to differentiation under the stated conditions. It did not demonstrate complete or selective inhibition of myostatin in an animal or human.
Is YK-11 a Myostatin Inhibitor?
YK-11 is frequently described commercially as a myostatin inhibitor, but this language is stronger than the research supports.
Myostatin, also known as growth differentiation factor 8, belongs to the transforming growth factor beta family. It participates in regulating skeletal muscle development and growth. After activation, myostatin can interact with activin type II receptors and influence intracellular SMAD signalling.
Follistatin can bind myostatin and reduce its ability to activate its receptor pathway. However, increasing follistatin expression in cultured cells is not identical to proving direct, selective or complete myostatin inhibition throughout a living organism.
The principal YK-11 study did not demonstrate direct binding between YK-11 and myostatin. It did not measure circulating myostatin in humans, establish a dose response relationship in human skeletal muscle or demonstrate functional myostatin inhibition in a clinical trial.
The most accurate scientific description is that YK-11 increased follistatin expression in a mouse muscle cell model and that follistatin contributed to the reported differentiation response. Whether this produces meaningful myostatin pathway modulation in humans has not been established.
Myogenic Differentiation and Muscle Growth
Myogenic differentiation is the process through which precursor cells develop towards a muscle cell phenotype. Researchers may examine cell shape, myotube formation, transcription factors and structural muscle proteins to evaluate this process.
An increase in differentiation markers does not automatically mean that a compound produces larger or stronger muscles in a living organism. Functional muscle development requires organised fibres, vascular supply, nerve connections, mechanical loading, adequate nutrients and coordinated tissue architecture.
Muscle mass and strength are also separate outcomes. A compound could alter gene expression or myotube formation without producing a meaningful improvement in force generation or physical performance.
The YK-11 findings should therefore be interpreted as mechanistic cellular evidence supporting further investigation. They do not constitute clinical evidence of muscle growth.
YK-11 and Bone Cell Research
A study published in 2018 examined YK-11 in MC3T3-E1 cells. This mouse cell line is widely used as a laboratory model of osteoblast development. Osteoblasts are involved in producing and mineralising bone matrix.
Researchers reported that YK-11 increased cellular proliferation and markers associated with osteoblast differentiation. The investigation included measurements involving alkaline phosphatase activity and osteoblast related gene expression. Androgen receptor involvement was also examined.
These results suggest that YK-11 can influence signalling within this particular bone cell model. They do not establish increased human bone density, improved bone strength or reduced fracture risk.
Bone is a complex living tissue affected by interactions among osteoblasts, osteoclasts, hormones, minerals, blood vessels and mechanical forces. Changes in a cultured osteoblast cell line represent an early mechanistic observation. Demonstrating a genuine skeletal benefit would require animal studies followed by controlled human research measuring bone density, structure, strength and clinical outcomes.
Human Research and Pharmacokinetic Gaps
There is no established body of controlled human clinical research defining YK-11 effectiveness, pharmacokinetics or safety. This separates YK-11 from compounds such as LGD-4033 and Ostarine, which have been investigated in controlled human studies.
There is no reliable published human evidence establishing YK-11 absorption, bioavailability, tissue distribution, metabolism, half life or elimination. There is also no controlled evidence demonstrating increased human lean body mass, muscle size, strength, bone density or physical function.
Commercial descriptions sometimes provide precise half life estimates or predictable outcome claims. These figures should be treated cautiously unless they can be traced to validated pharmacokinetic studies using authenticated YK-11.
Online reports cannot replace randomisation, chemical authentication, objective measurements or controlled monitoring. Personal accounts may also involve unverified products, additional substances, different quantities and unknown health factors.
The absence of human research does not prove that YK-11 has no biological activity. It means the magnitude, duration and consequences of that activity cannot be predicted reliably in humans.
Animal Research and Oxidative Stress
Animal research involving YK-11 remains limited compared with the evidence available for several other androgen receptor modulators.
A 2023 study examined YK-11 exposure in male rats and reported changes involving oxidative stress, mitochondrial function and protein regulation. Researchers observed alterations in endogenous antioxidant systems and findings consistent with increased oxidative and proteotoxic stress in the tissues examined.
Reactive oxygen species are not automatically harmful. They participate in normal cellular signalling. Excessive or poorly controlled accumulation can damage proteins, lipids and nucleic acids, while disruption of mitochondrial function can affect energy production and multiple tissue systems.
This research adds an important caution to the YK-11 evidence base. Cellular findings involving muscle or bone markers must be considered alongside emerging experiments investigating possible adverse effects.
Animal results cannot establish identical effects in humans, but they can reveal mechanisms and safety signals that justify further investigation. The lack of extensive toxicology and controlled human research means that YK-11’s overall safety profile remains poorly characterised.
Endocrine Effects and Other Unknowns
YK-11 interacts with the androgen receptor, making endocrine feedback a relevant research concern. Androgen receptor activation can influence hypothalamic and pituitary signalling, gonadotropins and endogenous sex hormone production.
Controlled human YK-11 studies have not established the magnitude, timing or recovery pattern of these effects. Claims that YK-11 produces a predictable degree of testosterone suppression are not supported by reliable clinical dose response research. Claims that it avoids endocrine suppression are equally unsupported.
Other major unknowns involve cardiovascular activity, lipid changes, reproductive toxicity, prostate effects, neurological activity and interactions with other compounds. Emerging animal research also raises questions about oxidative and mitochondrial stress.
A lack of documented adverse effects in clinical trials cannot be used as reassurance because those human trials do not exist. The correct conclusion is that these risks have not been adequately characterised.
Liver Related Evidence
Published reports involving SARMs have described liver injury, frequently with jaundice and a prolonged cholestatic pattern. Some reports involve single labelled compounds, while others involve several products or substances used together.
Many commercial preparations were not chemically authenticated before exposure. This makes it difficult to determine whether a reported injury was produced by the stated SARM, another active compound, an impurity or a combination of substances.
YK-11 has appeared in reports involving multiple SARM exposure, but these reports cannot produce a clean estimate of YK-11 specific liver risk. Its steroidal structure and androgen receptor activity make systematic liver research important, yet no controlled human programme has established the incidence or severity of possible effects.
Commercial product uncertainty creates an additional problem. A preparation labelled YK-11 may contain an incorrect quantity, another active compound or undeclared impurities. Meaningful safety interpretation requires verified chemical identity and accurate exposure information.
How YK-11 Differs from LGD-4033
YK-11 and LGD-4033 are both described as selective androgen receptor modulators, but their structures and research histories differ considerably.
LGD-4033 is a nonsteroidal compound with published pharmacokinetic and body composition data from a placebo controlled human trial. That study provides direct measurements involving blood concentrations, half life, lean body mass and short term endocrine markers.
YK-11 has a steroid derived structure and is supported mainly by mouse muscle and bone cell studies, with limited animal toxicology research. Equivalent controlled human measurements are not available.
This does not mean that LGD-4033 is approved or established as safe. It means researchers have substantially more direct human evidence available for interpreting its activity.
YK-11 should not be assumed to be more powerful because it was associated with follistatin expression. The compounds have not been compared in a robust controlled human study, and a cellular signalling result cannot establish comparative muscle effects.
YK-11 Is Not Follistatin
YK-11 is not follistatin and does not contain follistatin.
Follistatin is a naturally occurring protein involved in regulating activins and other members of the transforming growth factor beta family. YK-11 is a synthetic steroidal androgen receptor ligand that increased follistatin expression in one widely cited cellular study.
Exposing cells to YK-11, administering a follistatin protein and modifying follistatin gene expression are scientifically different strategies. Their pharmacokinetics, analytical requirements, biological effects and safety questions are not interchangeable.
A product marketed as YK-11 cannot be described as containing follistatin unless that protein is independently present and analytically identified.
Product Identity and the Commercial SARM Market
Research examining products marketed online as SARMs has identified frequent discrepancies between labels and measured contents. Some analysed preparations did not contain the stated SARM, while others contained undeclared active compounds. Measured quantities also frequently differed from label claims.
These findings are particularly important for YK-11 because there is no validated human pharmacokinetic profile against which an unverified commercial preparation can be evaluated.
A label stating YK-11 does not establish identity. A purity percentage alone does not prove that the main compound is YK-11 or that the stated quantity is accurate.
High performance liquid chromatography can assess chromatographic behaviour and estimate detectable impurities. It cannot independently establish complete molecular identity. Mass spectrometry can support identification by measuring molecular mass and fragmentation patterns, while nuclear magnetic resonance can provide more extensive structural information when required.
Quantitative analysis is also necessary. A sample can show a high purity percentage while containing less total YK-11 than claimed. Identity, purity and quantity must therefore be assessed as separate analytical questions.
Relevant quality assessment should consider the expected molecular mass, chromatographic comparison with suitable reference material, structural confirmation, stereochemistry, total compound quantity, residual solvents, synthesis related impurities and the connection between the tested sample and supplied batch.
Research Design for YK-11
Future YK-11 research should begin with chemically authenticated material and a precisely defined scientific question. In muscle cell models, researchers would need untreated and vehicle controls alongside a characterised androgen receptor agonist. An androgen receptor antagonist could help determine how much of the observed response depends on receptor activation. Follistatin should be measured at both gene and protein levels, while myostatin pathway activity should be assessed directly rather than inferred from follistatin expression alone.
Researchers would also need to distinguish cellular proliferation from genuine myogenic differentiation. Changes in cell number, gene expression or myotube appearance do not necessarily demonstrate the formation of structurally mature and functional muscle tissue. Bone cell research would require the same caution, with osteoblast markers examined alongside mineralisation, cellular viability and appropriate toxicity measurements.
Animal research would need to establish absorption, tissue distribution, metabolism and elimination while also examining endocrine markers, liver function, lipid measurements, reproductive effects and tissue histology. Any future human investigation would require extensive toxicology, ethical approval, authenticated material and carefully controlled clinical development. That evidence is not currently available, which prevents confident claims about human exposure, effectiveness or safety.
YK-11 and Competitive Sport
The World Anti Doping Agency lists YK-11 among selective androgen receptor modulators prohibited within the anabolic agents category. It is prohibited at all times for athletes governed by the World Anti Doping Code, including periods inside and outside competition.
Research use labelling does not change its status under sporting rules. Athletes remain responsible for prohibited substances detected in their samples, including substances originating from incorrectly labelled products.
Anti doping laboratories may examine both YK-11 and its metabolites using mass spectrometric methods. Metabolite detection is important because the parent compound may not remain the dominant urinary marker throughout the complete analytical detection period.
Major Evidence Limitations
YK-11 has a much smaller evidence base than commercial descriptions often imply.
• There are no established controlled human clinical trials.
• Human absorption, bioavailability, half life and elimination have not been reliably defined.
• No controlled study has demonstrated increased human muscle mass, strength or bone density.
• The principal evidence relies heavily on mouse muscle and osteoblast cell lines.
• Independent replication of the central follistatin findings remains limited.
• The research does not prove direct myostatin inhibition in humans.
• Animal research has raised questions involving oxidative and mitochondrial stress.
• Long term toxicology, endocrine effects and reproductive risks remain inadequately characterised.
• Commercial product identity and quantity cannot be assumed from a label or purity percentage.
These limitations do not make the cellular findings meaningless. They define the boundaries within which those findings can be interpreted responsibly.
Conclusion
YK-11 is a synthetic steroidal androgen receptor modulator investigated mainly in cellular models involving muscle differentiation, follistatin expression and osteoblast biology.
The best known study reported that YK-11 promoted differentiation in C2C12 mouse myoblasts and increased follistatin expression through an androgen receptor dependent pathway. This finding does not prove that YK-11 directly inhibits myostatin in humans or produces increased human muscle mass, strength or physical performance.
A separate study reported changes involving proliferation and differentiation in a mouse osteoblast cell line. These findings remain early cellular evidence and cannot establish improved human bone density or strength.
Emerging animal research has reported oxidative, mitochondrial and protein regulation disturbances, reinforcing the need to evaluate possible adverse effects alongside proposed anabolic activity.
There is no established human pharmacokinetic profile, controlled effectiveness trial or reliable long term safety database for YK-11. Claims involving precise human half life, predictable muscle growth or established safety therefore extend beyond the available evidence.
The current scientific position is that YK-11 is a highly experimental steroidal androgen receptor ligand with interesting cellular findings and substantial unanswered questions. Responsible research requires authenticated material, appropriate controls, direct measurement of claimed pathways and clear separation between laboratory observations and unsupported human claims.
Continue Exploring...
YK-11 Myostine
View BioPlex YK-11 Myostine research compound ⟶
YK-11 and S-23 Research Set
Explore the BioPlex YK-11 and S-23 research set ⟶
RAD-140, LGD-4033 and YK-11 Research Set
Explore the BioPlex triple SARM research set ⟶
SARMs Capsules
Explore BioPlex SARMs research compounds ⟶
SARMs Research Articles
Read BioPlex SARMs research articles and scientific guides ⟶
Peptide and Research Compound Testing
Explore BioPlex independent product testing ⟶
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
